Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Charles Schwab Investment Management Inc. decreased its stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 12.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,200 shares of the company’s stock after selling 16,049 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.21% of Prelude Therapeutics worth $149,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC grew its position in Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after purchasing an additional 12,564 shares during the last quarter. Geode Capital Management LLC grew its position in Prelude Therapeutics by 8.2% during the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after buying an additional 29,765 shares in the last quarter. XTX Topco Ltd bought a new position in Prelude Therapeutics during the third quarter valued at about $100,000. Walleye Capital LLC raised its holdings in Prelude Therapeutics by 446.2% in the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after acquiring an additional 67,946 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Prelude Therapeutics by 35.1% in the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after acquiring an additional 74,300 shares during the period. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Stock Up 0.3 %

Shares of PRLD opened at $0.77 on Wednesday. The company has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $1.23. The stock has a market cap of $42.49 million, a price-to-earnings ratio of -0.43 and a beta of 1.43. Prelude Therapeutics Incorporated has a 12 month low of $0.63 and a 12 month high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last posted its earnings results on Monday, March 10th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.11. The company had revenue of $4.00 million for the quarter. Equities research analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Insider Activity

In other news, insider Andrew Combs acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was bought at an average price of $0.69 per share, with a total value of $69,000.00. Following the completion of the acquisition, the insider now owns 480,123 shares in the company, valued at approximately $331,284.87. This represents a 26.31 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Krishna Vaddi bought 47,500 shares of Prelude Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average cost of $0.71 per share, for a total transaction of $33,725.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,214,775 shares in the company, valued at $862,490.25. This represents a 4.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 822,500 shares of company stock worth $568,475. Corporate insiders own 62.80% of the company’s stock.

Prelude Therapeutics Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.